Cost-effective and scalable means for detecting amyloid-β positivity in clinical practice are urgently needed. Here, in three memory clinic cohorts, we show that risk stratification with a plasma p-tau217-based model can substantially reduce the need for expensive or invasive testing, while still accurately determining the amyloid-β status of patients with cognitive impairment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hansson, O. Biomarkers for neurodegenerative diseases. Nat Med. 27, 954–963 (2021). A comprehensive review of currently available biomarkers for neurodegenerative diseases.
Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nat. Aging 3, 506–519 (2023). A review describing the most promising blood-based biomarkers for AD and the steps needed for clinical implementation.
Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 18, 2669–2686 (2022). International recommendations on how to use blood-based biomarkers for AD in clinical practice and trials.
Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain 146, 1592–1601 (2023). Comparison of the most promising plasma p-tau assays used for AD detection.
Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 19, 1913–1924 (2023). Another comparison of promising plasma p-tau assays for AD that also shows a high performance for p-tau217.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nat. Aging, https://doi.org/10.1038/s43587-023-00471-5 (2023).
Rights and permissions
About this article
Cite this article
Cost-effective Alzheimer’s disease detection using plasma p-tau217-based risk stratification. Nat Aging 3, 1053–1054 (2023). https://doi.org/10.1038/s43587-023-00485-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-023-00485-z
